|
|
Article: Financings Roundup The 'Rights' Stuff: Offering Gains Pharmacyclics $24M.
- Article from:
- BIOWORLD Today
- Article date:
- July 17, 2009
- Author:
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Byline: Jennifer Boggs, Assistant Managing Editor
Rebounding from its 2007 troubles with lung cancer drug Xcytrin, Pharmacyclics Inc. has emerged with a retooled management team, a multiproduct pipeline and a rather unusual -- at least for biotech -- money-raising strategy.
Rather than trying to brave the public markets or risk significant dilution through a PIPE investment, the Sunnyvale, Calif.-based firm has opted for a rights offering -- making about 18.8 million shares of its stock available to current stakeholders for $1.28 each -- hoping to pad its lean balance sheet by $24 million. It's the company's first fundraising since Robert Duggan stepped ...
Related newspaper, magazine, and journal articles:
|
|
Article: COMPANY FORGING AHEAD WITH DIABETES DRUG AMYLIN STOCK DROPS 77 ...
BIOWORLD Today;
October 22, 1998 ;
700+ words
... ... price dropped below $8.50. (See BioWorld Today, Aug. 19, 1997, p. 1.) Along ... U.S. and Europe," Krawiec told BioWorld Today. Tanner said Amylin's move to continue ... J $36 million from a loan. (See BioWorld Today, March 3, 1998, p. 1.) Terms ...
|
|